Butterfly Network surges 56% as Midjourney unveils ultrasound-on-chip scanner targeting 50,000 units by 2031

Butterfly Network Incorporated (NYSE: BFLY) shares jumped 55.87 percent on June 18 to close at $8.90, marking the best single-session and best week in the Burlington, Massachusetts-based medical imaging company’s history, after Midjourney unveiled the Midjourney Medical division and its first commercial product, a whole-body ultrasound scanner built on Butterfly Network’s Ultrasound-on-Chip semiconductor platform. The current scanner prototype incorporates 40 Butterfly Ultrasound-on-Chip imaging modules under a co-development and licensing agreement signed last year, with potential payments reaching $74 million over five years and additional revenue contingent on scaled deployment. Midjourney disclosed plans to open a flagship Midjourney Spa in San Francisco by the end of 2027 with 10 scanners, expand to additional cities in 2028, and ultimately operate over 50,000 scanners worldwide by 2031 with capacity for one billion scans per month, a target that would represent roughly 80 to 120 times the current global MRI market of 100 to 150 million annual scans. The stock has subsequently traded with elevated volatility around the new levels, gaining roughly 7.11 percent on Friday June 26 before reversing into the close, with the rally cementing year-to-date gains near 100 percent and trailing twelve months returns exceeding 312 percent. Famed investor Michael Burry publicly praised the platform validation, while TD Cowen analyst Joshua Jennings noted that the launch underscores the potentially underappreciated value of Butterfly Network’s Ultrasound-on-Chip platform as a foundation for entirely new imaging applications.

What the Midjourney Medical scanner launch actually signals about the Butterfly Network platform thesis

The Midjourney Medical scanner launch represents the most significant external validation of the Butterfly Network Ultrasound-on-Chip platform since the original handheld iQ probe commercialization. Midjourney is a profitable, bootstrapped artificial intelligence company best known for its image generation services, and the decision to pursue medical imaging hardware as its first major product expansion required substantial diligence into available semiconductor ultrasound technology. The selection of Butterfly Network’s chip over alternative ultrasound technologies signals that the Ultrasound-on-Chip platform has reached technical maturity sufficient to anchor a flagship hardware product with substantial commercial ambition.

The deeper signal in the partnership structure deserves analytical attention. The five-year licensing and co-development agreement provides Butterfly Network with multi-year revenue visibility from Midjourney specifically, while the broader strategic implication validates Butterfly Network’s thesis that the Ultrasound-on-Chip platform can scale beyond handheld point-of-care imaging into entirely new device categories. The handheld ultrasound business that has anchored Butterfly Network’s commercial activity through the past several years targets a specific clinical workflow, while the Midjourney scanner targets consumer wellness and preventive health applications that operate on fundamentally different commercial dynamics, distribution channels and pricing structures.

The technical architecture of the Midjourney scanner provides interesting context for evaluating the broader platform applicability. The scanner uses approximately 500,000 ultrasonic sensors arranged in a ring through which users pass while immersed in warm water, generating terabytes of imaging data that artificial intelligence and high-performance computing systems process into MRI-comparable body maps within approximately 60 seconds. The 40 Butterfly Ultrasound-on-Chip imaging modules per scanner provide the sensor infrastructure that the ring assembly requires, and the modular architecture allows scaling to higher module counts in subsequent scanner generations to deliver higher resolution and faster acquisition speeds.

The competitive context for medical imaging makes the Midjourney scanner thesis particularly aggressive. Magnetic resonance imaging has been the dominant cross-sectional anatomical imaging modality for decades, with substantial installed base, established clinical workflows and payer reimbursement infrastructure. The Midjourney scanner attempts to compete with MRI on a fundamentally different basis, offering substantially lower cost per scan, faster acquisition times and consumer-accessible deployment models that bypass the traditional medical facility workflow. The execution risk is substantial because the clinical equivalence to MRI for diagnostic purposes has not been validated, and the regulatory approval pathway for consumer-deployed full-body imaging faces complexity that Midjourney will need to navigate.

The second-order observation concerns the implications for the established medical imaging incumbents. GE HealthCare, Philips, Siemens Healthineers and Canon Medical Systems dominate the high-end imaging equipment market with MRI, computed tomography and traditional ultrasound platforms. A successful Midjourney scanner deployment would not directly replace these technologies for most clinical applications, but it would create alternative consumer access to body imaging that historically required medical facility infrastructure. The competitive read-across affects the long-term growth trajectories of the imaging incumbents, particularly in preventive screening applications where consumer access models could displace traditional clinical pathways.

Why the $74 million Midjourney payment structure and back-loaded timing temper the immediate financial impact

The financial structure of the Midjourney partnership warrants careful analytical attention because the headline $74 million figure obscures the timing and conditionality of the payment cadence. The agreement structure includes upfront payments, milestone-based payments tied to scanner deployment volumes and ongoing royalty payments calibrated to scanner production. The total payment cap of $74 million across five years implies average annual contribution of approximately $14.8 million, but the actual payment timing concentrates substantially in the later years of the agreement as Midjourney scales scanner production toward its 2031 deployment targets.

The Seeking Alpha analytical framework that modeled the Midjourney optionality at $1.50 to $2 per share against the post-rally trading levels captures the disconnect between the headline partnership announcement and the underlying economic value. Butterfly Network’s market capitalization expanded by approximately $200 to $300 million on the partnership announcement, while the discounted present value of the maximum $74 million payment stream over five years sits well below that capitalization expansion. The market is paying for the optionality of the broader Midjourney scaling roadmap rather than the explicit contracted payments alone.

The execution risk concentrates in three operational variables that will determine whether the Midjourney scaling roadmap actually materializes. First, regulatory approval for consumer-deployed full-body imaging faces complexity that exceeds traditional medical imaging device approval pathways. The combination of ultrasound technology, artificial intelligence image processing and consumer wellness positioning creates regulatory questions that the Food and Drug Administration has not previously addressed at this scale. Second, the consumer demand for full-body imaging at the price points Midjourney has implied remains untested, particularly for routine preventive scanning rather than clinically indicated diagnostic procedures. Third, the manufacturing scale-up from prototype scanners to 50,000 globally deployed units requires manufacturing infrastructure and quality systems that neither Midjourney nor Butterfly Network currently operates.

The custom silicon transition disclosed by Midjourney adds an additional consideration that affects the long-term Butterfly Network economics. Midjourney has indicated that its third-generation scanner will incorporate custom silicon rather than the current Butterfly Network Ultrasound-on-Chip modules, which would substantially reduce or eliminate the per-unit licensing payments that Butterfly Network receives from each scanner deployment. The third-generation timeline likely aligns with the 2028 to 2029 commercial deployment phase, which means the Butterfly Network revenue contribution from Midjourney specifically may peak during the 2026 to 2028 ramp before declining as custom silicon replaces the Butterfly Network modules.

The strategic value of the partnership therefore extends beyond the direct payment stream into broader platform validation effects. The Midjourney decision to license Butterfly Network technology creates implicit validation that other partners can use to justify their own evaluations of the Ultrasound-on-Chip platform. The David Horsley appointment as Senior Vice President of Innovation for Butterfly Embedded specifically positions the company to capture the broader licensing opportunity that the Midjourney validation has surfaced, and subsequent embedded deals across consumer electronics, medical devices and industrial applications could collectively exceed the direct Midjourney revenue contribution.

How the Aleph Neuro brain imaging partnership and broader embedded thesis reshape the Butterfly Network revenue mix

The Aleph Neuro collaboration disclosed on June 26 provides the first additional validation point for the broader Butterfly Embedded licensing thesis. Aleph Neuro used the Butterfly Network platform to create high-resolution, non-invasive three-dimensional brain images, which extends the platform applicability beyond the soft-tissue imaging that has anchored traditional ultrasound applications into the neurological imaging category that has historically required MRI or computed tomography infrastructure. The brain imaging application represents a particularly meaningful technical achievement because ultrasound has not traditionally been considered competitive with MRI for detailed brain anatomy visualization.

The strategic significance of the Aleph Neuro validation extends beyond the specific brain imaging application. The willingness of an additional technology partner to deploy the Butterfly Network platform for a non-traditional ultrasound use case demonstrates that the Midjourney partnership is not an isolated event but part of a broader pattern where the Ultrasound-on-Chip platform is being evaluated and deployed across multiple emerging imaging applications. The pattern supports the bull case that Butterfly Network has positioned itself as the default semiconductor ultrasound supplier for the broader emerging imaging applications category.

The DESKi HeartFocus AI integration with Butterfly Network probes provides a third validation point that anchors the AI ecosystem partner narrative. The integration enables clinician-friendly echocardiography workflows for users with less specialized cardiac imaging training, which expands the addressable market for cardiac ultrasound applications beyond the traditional cardiology specialist user base. The combination of Butterfly Network hardware with DESKi AI software creates a platform-level value proposition that pure-play ultrasound hardware competitors cannot easily replicate.

The Butterfly Garden and Compass AI platforms represent Butterfly Network’s own software and AI infrastructure that complements the hardware platform. The combination of hardware, embedded licensing and proprietary AI software creates the kind of integrated platform architecture that the broader medical imaging industry has been moving toward, where individual technology components are less valuable than integrated workflow solutions. The integrated platform positioning supports premium pricing and customer retention dynamics that pure-play hardware vendors cannot achieve.

The third-order consideration concerns the broader pattern of semiconductor-based imaging platforms supplanting traditional dedicated imaging equipment. The Butterfly Network thesis effectively argues that semiconductor manufacturing economics applied to ultrasound transducers will progressively displace the discrete piezoelectric crystal transducer technology that has anchored ultrasound equipment for several decades. The pattern parallels broader semiconductor industry trends where dedicated discrete components have been progressively integrated into application-specific integrated circuits with substantially lower production costs and higher reliability characteristics. If the pattern plays out as the Butterfly Network thesis implies, the company occupies a structurally advantageous position at the center of the ultrasound industry transition.

What the Butterfly Network financial profile and insider activity mean for the equity positioning

The financial profile beneath the equity rally remains structurally challenging despite the operational momentum that the partnership disclosures have generated. Butterfly Network reported first-quarter 2026 revenue of $26.5 million, up 25 percent year over year, with gross margin climbing to 68.9 percent. The company maintained its 2026 revenue outlook of $117 million to $121 million, which represents continued operational scale expansion but remains modest in absolute terms relative to the current market capitalization. Trailing twelve months operating losses of approximately $75.8 million reflect the ongoing investment in research and development, commercial expansion and platform development that the broader strategy requires.

The Simply Wall St analytical framework projects revenue of $167.0 million and earnings of $20.4 million by 2029, which requires 17.5 percent annual revenue growth and a $96.2 million earnings improvement from the current trailing twelve months negative base. The framework yields a fair value estimate of $5.69 per share, representing approximately 22 percent downside from current trading levels. The bearish analytical case argues that the equity has substantially overshot the underlying operational trajectory and faces meaningful downside risk if the operational delivery falls short of the optimistic scenarios.

The insider selling pattern adds an additional layer of caution that institutional investors are evaluating. Butterfly Network insiders have executed 20 open-market sales over the past six months with zero purchases, indicating systematic divestment by the management and founder team during the recent rally phase. Founder Jonathan Rothberg sold approximately 1.2 million shares for an estimated $4.9 million, Chief Business Officer Steve Cashman sold approximately 1.0 million shares for an estimated $4.9 million, Chief Executive Officer Joseph DeVivo sold approximately 643,000 shares for an estimated $2.4 million, and additional senior executives executed smaller scale sales. The aggregate insider selling pattern represents one of the more concentrated divestment programs in the small-cap healthcare equity universe and creates an implicit signal about insider confidence in the elevated valuation.

The institutional accumulation activity provides the offsetting positioning consideration. Glenview Capital Management added 4.4 million shares representing a 44 percent position increase, Nuveen LLC added 3.2 million shares representing a 579 percent position increase, Algert Global LLC added 2.3 million shares representing a 597 percent position increase, Marshall Wace LLP added 1.9 million shares representing a 444 percent position increase, and Jane Street Group added 1.1 million shares representing a 123 percent position increase. The substantial institutional accumulation during the first quarter of 2026 indicates that sophisticated institutional capital has been positioning in Butterfly Network ahead of the catalyst flow that has now materialized, which provides offsetting validation against the insider selling pattern.

The analyst coverage remains relatively limited with three analysts publishing price targets in the past six months, with a median target of $5.50. The dispersion in analyst views, combined with the limited coverage breadth, captures the early-stage analytical positioning that the broader institutional sell-side maintains on Butterfly Network. Additional analyst coverage and price target updates over the coming weeks will provide further institutional read-through on the appropriate valuation framework for the post-partnership operational trajectory.

What the Butterfly Network rally means for medical imaging peers and the broader semiconductor ultrasound category

The read-across from the Butterfly Network rally extends across the broader medical imaging and semiconductor ultrasound categories. The most direct beneficiaries are companies developing competing semiconductor-based ultrasound technologies, although the competitive landscape remains fragmented and Butterfly Network maintains a leading position in commercial deployment. The validation of the broader Ultrasound-on-Chip thesis through the Midjourney and Aleph Neuro partnerships supports the longer-term growth trajectory for the entire emerging semiconductor ultrasound category.

The established medical imaging equipment manufacturers face mixed read-across implications. GE HealthCare, Philips and Siemens Healthineers operate substantial ultrasound businesses alongside their MRI, computed tomography and other imaging modalities. The successful expansion of semiconductor ultrasound into emerging applications represents a competitive threat to the traditional dedicated transducer architecture that the incumbents have historically dominated, but it also represents an opportunity for the incumbents to incorporate semiconductor ultrasound technology into their own product portfolios through licensing or strategic partnership arrangements.

The artificial intelligence in medical imaging category benefits broadly from the Midjourney expansion into healthcare hardware. Companies developing AI imaging interpretation software, AI-assisted clinical workflows and AI-driven diagnostic algorithms gain validation through the demonstration that consumer-scale AI companies are willing to invest in healthcare hardware as a flagship application. The pattern supports broader institutional interest in the medical imaging AI category, even though individual companies will face their own specific competitive dynamics and execution risks.

The consumer wellness and preventive health category positioning by Midjourney represents an emerging market category that affects multiple adjacent companies. The Apple Watch, Oura Ring and various other consumer health monitoring technologies have built substantial businesses around health tracking, and the Midjourney scanner extends that consumer health positioning into the diagnostic imaging category. The broader consumer wellness market dynamics will affect Butterfly Network indirectly through the Midjourney scanner deployment, with consumer adoption of preventive imaging services determining the eventual scale of the partnership economics.

The point-of-care ultrasound competitive landscape includes GE HealthCare’s Vscan, Philips Lumify, Clarius Mobile Health, and various other handheld ultrasound systems. Butterfly Network’s handheld iQ product line competes directly in this category, and the broader platform momentum supports the company’s position in the core point-of-care category even as the embedded licensing thesis expands beyond handheld applications. The competitive structure in handheld ultrasound continues to evolve as semiconductor-based and dedicated transducer products compete for share, with Butterfly Network’s integrated platform approach providing differentiation that pure-play hardware competitors find difficult to replicate.

Key takeaways on what the Butterfly Network rally means for the company, peers and the medical imaging industry

• The 55.87 percent single-session rally to $8.90 on June 18 marked the best day in Butterfly Network history and reflected substantial external validation of the Ultrasound-on-Chip platform thesis through the Midjourney Medical scanner launch.
• The five-year co-development and licensing agreement with Midjourney provides potential payments up to $74 million, with the actual cadence back-loaded toward 2028 and conditional on scanner deployment volume targets.
• Midjourney’s roadmap targeting 50,000 deployed scanners worldwide by 2031 with capacity for one billion scans per month would represent 80 to 120 times the current global MRI market of 100 to 150 million annual scans.
• The third-generation Midjourney scanner is expected to incorporate custom silicon rather than Butterfly Network Ultrasound-on-Chip modules, which constrains the long-term direct revenue contribution from the partnership beyond the initial scaling phase.
• The Aleph Neuro collaboration extending into three-dimensional brain imaging and the DESKi HeartFocus AI integration on Butterfly Network probes demonstrate that the platform validation extends beyond the Midjourney partnership into additional embedded licensing opportunities.
• First-quarter 2026 revenue of $26.5 million up 25 percent year over year, with gross margin at 68.9 percent and full-year guidance of $117 to $121 million, provides the operational foundation that the broader platform thesis builds upon.
• Insider selling of $4.9 million by founder Jonathan Rothberg and similar scale divestments by senior management creates an implicit signal about confidence in current valuation that institutional investors are evaluating.
• Institutional accumulation during the first quarter of 2026 including Glenview Capital, Nuveen, Algert Global, Marshall Wace and Jane Street represents substantial sophisticated capital positioning ahead of the catalyst flow that has now materialized.
• The Simply Wall St fair value estimate of $5.69 per share against current trading levels above $7 captures the analytical tension between the optimistic platform validation thesis and the more conservative operational trajectory.
• The principal risks ahead are Midjourney scanner regulatory approval and consumer adoption uncertainty, the custom silicon transition in third-generation scanners that constrains long-term partnership economics, the persistent insider selling pattern, and the broader execution requirements for the embedded licensing thesis to translate into commercial revenue at the scale that current valuation implies.